Clinical trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma
17 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGEarly Phase 1NCT07162012Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive LymphomaShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGPhase 2NCT06846463Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+Virginia Commonwealth University · PI: Bruce Hough, MD
- RECRUITINGPhase 3NCT06929624A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell LymphomaSuzhou Suncadia Biopharmaceuticals Co., Ltd.
- RECRUITINGPhase 1NCT06830031Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell LymphomaShanghai Exuma Biotechnology Ltd. · PI: Liang Huang, MD
- RECRUITINGNCT07198230Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell LymphomaTing YANG
- RECRUITINGPhase 2NCT07254754Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell LymphomaGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea · PI: Mariana Bastos-Oreiro
- RECRUITINGPhase 3NCT06522555The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaRuijin Hospital
- RECRUITINGPhase 2NCT05934448Pembro Plus CAR T-cell Therapy in R/R in PMBCLJennifer Crombie, MD · PI: Jennifer Crombie, MD
- RECRUITINGPhase 2NCT05633615Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaSWOG Cancer Research Network · PI: Brian T Hess
- RECRUITINGNCT05725720Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell TherapyUniversity of Bologna
- ACTIVE NOT RECRUITINGN/ANCT05675982Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T CellsCentre Henri Becquerel · PI: Vincent Camus, MD
- RECRUITINGNCT05377307Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell TherapyPell Bio-Med Technology Co., Ltd. · PI: Chen-Lung Lin, MD
- ACTIVE NOT RECRUITINGPhase 2NCT05563844Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)Chengdu Zenitar Biomedical Technology Co., Ltd · PI: Ting Niu, Doctor
- RECRUITINGPhase 2NCT05257018R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS RelapseFudan University · PI: Dongmei Ji, doctor
- ACTIVE NOT RECRUITINGPhase 3NCT04628494A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)Genmab
- ACTIVE NOT RECRUITINGPhase 1NCT0446420019(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell CancersMemorial Sloan Kettering Cancer Center · PI: Jae Park, MD
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT03984448Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell LymphomasNational Cancer Institute (NCI) · PI: Jeremy S Abramson